Combination with gamma secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF mutant melanoma cells

被引：0
|
作者：
Zhu, G. [1 ,2 ]
Yi, X. [1 ]
Haferkamp, S. [3 ]
Hesbacher, S. [2 ]
Li, C. [1 ]
Goebeler, M. [2 ]
Gao, T. [1 ]
Houben, R. [2 ]
Schrama, D. [2 ]
机构：
[1] Fourth Mil Med Univ, Dermatol, Xian, Peoples R China
[2] Univ Hosp Wurzburg, Dermatol, Wurzburg, Germany
[3] Univ Regensburg, Dermatol, Regensburg, Germany
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2016年 / 136卷 / 05期
关键词：
D O I：
10.1016/j.jid.2016.02.699
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
658
引用
收藏
页码：S116 / S116
页数：1
相关论文
共 50 条
  • [31] Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment
    Wilmott, James S.
    Haydu, Lauren E.
    Menzies, Alexander M.
    Lum, Trina
    Hyman, Jessica
    Thompson, John F.
    Hersey, Peter
    Kefford, Richard F.
    Scolyer, Richard A.
    Long, Georgina V.
    JOURNAL OF IMMUNOLOGY, 2014, 192 (05): : 2505 - 2513
  • [32] The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells
    Yu, Ling
    Favoino, Elvira
    Wang, Yangyang
    Ma, Yang
    Deng, Xiaojuan
    Wang, Xinhui
    IMMUNOLOGIC RESEARCH, 2011, 50 (2-3) : 294 - 302
  • [33] BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma
    Richman, Juliet
    Martin-Liberal, Juan
    Diem, Stefan
    Larkin, James
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (09) : 1285 - 1297
  • [34] Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In Vivo
    Niessner, Heike
    Burkard, Markus
    Leischner, Christian
    Renner, Olga
    Ploeger, Sarah
    Meraz-Torres, Francisco
    Boecker, Matti
    Hirn, Constanze
    Lauer, Ulrich M.
    Venturelli, Sascha
    Busch, Christian
    Sinnberg, Tobias
    CELLS, 2022, 11 (07)
  • [35] Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma
    Diab, Adi
    Martin, Alison
    Simpson, Lauren
    Algazi, Alain Patrick
    Chawla, Purvi
    Kim, Dae Won
    Santra, Sourav
    Patel, Vruti
    Jadhav, Nitin
    Abhyankar, Dhiraj
    Davies, Michael A.
    Buch, Shama C.
    Kim, Kevin
    Daud, Adil
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Is there any interest in a new BRAF-MEK inhibitor combination in melanoma?
    Grob, Jean Jacques
    LANCET ONCOLOGY, 2018, 19 (05): : 580 - 581
  • [37] BRAF inhibitor GSK2118436-single agent and combination activity with other targeted agents in BRAF V600 mutant melanoma
    Greger, James G.
    Eastman, Stephen D.
    Shi, Hong
    Zhang, Vivian
    Hughes, Ashley
    Liu, Li
    Gilmer, Tona M.
    CANCER RESEARCH, 2012, 72
  • [38] Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study
    Liu, Xing
    Li, Jing-jing
    Ding, Ya
    Li, Dan-dan
    Wen, Xi-zhi
    Weng, De-sheng
    Wang, Jiu-hong
    Jiang, Hang
    Zhang, Xiao-shi
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [39] MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor
    Aida, Satoshi
    Sonobe, Yukiko
    Tanimura, Hiromi
    Oikawa, Nobuhiro
    Yuhki, Munehiro
    Sakamoto, Hiroshi
    Mizuno, Takakazu
    CANCER LETTERS, 2017, 409 : 116 - 124
  • [40] Optimizing the treatment of BRAF mutant melanoma
    Settleman, Jeff
    GENOME MEDICINE, 2014, 6
12345